{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:36:47Z","timestamp":1793824607151,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Arricale Family Research Fund"},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Huayi and Siuling Zhang Discovery Fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.rmed.2019.05.012","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T21:20:10Z","timestamp":1558387210000},"page":"6-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-4855","authenticated-orcid":false,"given":"J.A.","family":"Huapaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hallowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Silhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6338-9218","authenticated-orcid":false,"given":"I.","family":"Pinal-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Casal-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Albayda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hussien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Danoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2019.05.012_bib1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2019.05.012_bib2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/BOR.0000000000000104","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances","volume":"26","author":"Hallowell","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"issue":"5","key":"10.1016\/j.rmed.2019.05.012_bib3","first-page":"1012","article-title":"Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis","volume":"34","author":"Matsushita","year":"2007","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.rmed.2019.05.012_bib4","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/kep455","article-title":"Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases","volume":"49","author":"Hervier","year":"2010","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rmed.2019.05.012_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2019.05.012_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/joim.12511","article-title":"Update on the pharmacological treatment of adult myositis","volume":"280","author":"Oddis","year":"2016","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.rmed.2019.05.012_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","article-title":"Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment","volume":"14","author":"Mimori","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.rmed.2019.05.012_bib8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2019.05.012_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/BOR.0000000000000270","article-title":"Management of connective tissue diseases associated interstitial lung disease: a review of the published literature","volume":"28","author":"Wallace","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.rmed.2019.05.012_bib10","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai","year":"2016","journal-title":"Br. Med. J."},{"issue":"7","key":"10.1016\/j.rmed.2019.05.012_bib11","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"issue":"11","key":"10.1016\/j.rmed.2019.05.012_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.rmed.2019.05.012_bib13","first-page":"296","article-title":"Rituximab for the treatment of connective tissue disease-associated interstitial lung disease","volume":"32","author":"Chartrand","year":"2016","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis.: Off. J. WASOG\/ World Assoc. Sarcoidosis Other Granulomatous Disord."},{"issue":"2","key":"10.1016\/j.rmed.2019.05.012_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2019.05.012_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2332\/allergolint.55.199","article-title":"Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis","volume":"55","author":"Murota","year":"2006","journal-title":"Allergol. Int.: Off. J. Jpn. Soc. Allergol."},{"issue":"2","key":"10.1016\/j.rmed.2019.05.012_bib16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis","volume":"140","author":"Diot","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2019.05.012_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.rmed.2019.05.012_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00296-003-0422-0","article-title":"Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases","volume":"25","author":"Kamali","year":"2005","journal-title":"Rheumatol. Int."},{"issue":"19","key":"10.1016\/j.rmed.2019.05.012_bib19","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.rmed.2019.05.012_bib20","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2019.05.012_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod. Rheumatol.\/Jpn. Rheumatism.Assoc."},{"issue":"1","key":"10.1016\/j.rmed.2019.05.012_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito","year":"2008","journal-title":"Mod. Rheumatol.\/Jpn. Rheumatism Assoc."},{"issue":"3","key":"10.1016\/j.rmed.2019.05.012_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11926-011-0171-0","article-title":"Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease","volume":"13","author":"Quick","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"issue":"10","key":"10.1016\/j.rmed.2019.05.012_bib24","first-page":"1682","article-title":"Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease","volume":"13","author":"Hallowell","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"2","key":"10.1016\/j.rmed.2019.05.012_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.rmed.2019.05.012_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.rmed.2019.05.012_bib27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"6 Pt 1","key":"10.1016\/j.rmed.2019.05.012_bib28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0190-9622(91)70153-S","article-title":"Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature","volume":"24","author":"Euwer","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.rmed.2019.05.012_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.rmed.2019.05.012_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin. Immunol.: Off. J. Can. Soc. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2019.05.012_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-12-93","article-title":"The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial","volume":"12","author":"Taniguchi","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2019.05.012_bib32","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","author":"Kafaja","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2019.05.012_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","article-title":"Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial","volume":"17","author":"Behr","year":"2017","journal-title":"BMC Pulm. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:48:41Z","timestamp":1760615321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119301647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"alternative-id":["S0954611119301647"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.05.012","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}